This report provides exclusive insights into the COVID-19 impact on the Engineered T Cells Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Engineered T Cells Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Engineered T Cells Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on engineered T cells market provides in-depth analysis of segments and sub-segments in global as well as regional engineered T cells market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional engineered T cells market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global engineered T cells market. According to the report, the global engineered T cells market is projected to grow at a healthy CAGR over the forecast period of 2018-2024.
Engineered T cells are also known as specifically modified T cells that are designed for the treatment of cancer, primary immune deficiencies, and autoimmune diseases. These cells are being used for research and therapeutic purposes that contain tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR), T cell receptor (TCR). Engineered T cells allow reduction of toxicities and inhibit antigen escape. Engineered T cells mainly help to detect target cancer cells in the immune system. Furthermore, for effective treatment engineered T cells help in immunosuppressive tumor microenvironments.
The growing incidence of different types of cancers and autoimmune diseases are driving the growth of the engineered T cells market. Besides this, advantages offered by engineered T cell therapies above traditional cancer treatments such as chemotherapy are the major factors boosting the market growth for the same. Additionally, increase approach to medical insurance fuels the demand for engineered T cells market. On the contrary, the potential risk of engineered T cell treatments and the high cost of treatments obstruct the growth of this market.
As per the geographies, North America is expected to acquire the maximum market share during the forecast period. Due to the rise in the occurrence of cancer and the existence of well-established biopharmaceutical companies & advanced biotech research facilities is driving the growth of engineered T cell market in the North America region. Furthermore, government enthusiasm to modernize healthcare infrastructure growth in a number of biopharmaceutical start-ups in the Asia-Pacific region is anticipated to support the growth of engineered T cells market in this region.
The report on global engineered T cells market covers segments such as type, application, and end user. On the basis of type, the global engineered T cells market is categorized into tumor infiltrating lymphocytes, T cell receptor (TCR), and chimeric antigen receptor (CAR). On the basis of application, the global engineered T cells market is categorized into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and others. On the basis of the end user, the global engineered T cells market is categorized into hospitals, cancer research centers, and clinics.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while the Asia-Pacific region includes countries such as China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are the major markets included in the European region. The U.S. drives the growth in the North America region, as it is the largest market in the region. In the Asia-Pacific region, rapid industrial growth in India and China offer substantial potential for the growth in the engineered T cells market. As a result, the APAC region is projected to experience growth at a CAGR of x.x% over the forecast period 2018-2024.
The report provides profiles of the companies in the global engineered T cells market such as Autolus, Precision Biosciences., Pfizer Inc., Bellicum Pharmaceuticals, Inc., Cell Medica., Oxford BioMedica, Elli Lilly and Company, Novartis AG, Gilead, and Juno Therapeutics, Inc.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global engineered T cells market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of engineered T cells market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the engineered T cells market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the engineered T cells market to understand the present and future trends in this market and formulate their strategies accordingly.